Lamotrigine in treatment-resistant schizophrenia: A randomized placebo-controlled crossover trial

Biological Psychiatry

Volumn 54, Issue 11, 2003, Pages 1241-1248

  Tiihonen, Jari ^a,b,c,e   Hallikainen, Tero ^b   Ryynänen, Olli Pekka ^b   Repo Tiihonen, Eila ^b   Kotilainen, Irma ^b   Eronen, Markku ^d   Toivonen, Päivi ^d   Wahlbeck, Kristian ^a   Putkonen, Anu ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d VANHA VAASA HOSPITAL   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Lamotrigine; Randomized; Schizophrenia; Treatment resistant; Trial

Indexed keywords

ANTICONVULSIVE AGENT; CLOZAPINE; LAMOTRIGINE; PLACEBO;

ADULT; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EJACULATION DISORDER; HEART PALPITATION; HUMAN; HYPERSALIVATION; MALE; MEMORY DISORDER; MUSCLE RIGIDITY; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCHIZOPHRENIA; SEDATION; TREATMENT OUTCOME; VERTIGO;

EID: 0142095347     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00524-9     Document Type: Article

References (43)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed :1994;American Psychiatric Association, Washington, DC.
2. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 57:2000;270-276.
3. Bowden C.L., Karren N.U. Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother. 3:2002;1513-1519.
4. Calabrese J.R., Shelton M.D., Rapport D.J., Kimmel S.E., Elhaj O. Long-term treatment of bipolar disorder with lamotrigine. J Clin Psychiatry. 63:(suppl 10):2002;18-22.
5. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 20:1960;37-46.
6. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 1977;Academic Press Inc, Orlando, FL.
7. Cousin M.B., Nicholls D.G., Pocock J.M. Flunarizine inhibits both calcium-dependent and independent release of glutamate from synaptosomes and cultured neurones. Brain Res. 606:1993;227-236.
8. Deakin J.F., Slater P., Simpson M.D., Gilchrist A.C., Skan W.J., Royston M.C., et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem. 52:1989;1781-1786.
9. Dursun S.M., Deakin J.F.W. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia A naturalistic case-series outcome study . J Psychopharmacol. 15:2001;297-301.
10. Dursun S.M., McIntosh D., Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry. 56:1999;950.
11. Evins A.E., Fitzgerald S.M., Wine L., Roselli R., Goff D.C. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 157:2000;. 826-628.
12. Faraone S.V., Biederman J., Spencer T.J., Wilens T.E. The drug-placebo response curve A new method for assessing drug effects in clinical trials . J Clin Psychopharmacol. 6:2000;673-679.
13. Farber N.B., Newcomer J.W., Olney J.W. The glutamate synapse in neuropsychiatric disorders Focus on schizophrenia and Alzheimers disease . Prog Brain Res. 116:1998;421-437.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0, 4/97 revision). 1997;Biometrics Research Department, New York State Psychiatric Institute, New York.
15. Goff D., Henderson D., Evins A., Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 45:1999;512-514.
16. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 158:2001;1367-1377.
17. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 152:1995;1213-1215.
18. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 153:1996;1628-1630.
19. Grunze H., Greene R.W., Moller H.J., Meyer T., Walden J. Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current. Brain Res. 791:1998;330-334.
20. Heresco-Levy U., Javitt D., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 169:1996;610-617.
21. Heresco-Levy U., Javitt D., Ermilov M., Mordel C., Silipo G., Lichenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 56:1999;29-36.
22. Hurley S.C. Lamotrigine update and its use in mood disorders. Ann Pharmacother. 36:2002;860-873.
23. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials Is blinding necessary? Control Clin Trials. 17:1996;1-12.
24. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
25. Kane J., Honigfelfd G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 45:1988;789-796.
26. Kane J.M. The current status of neuroleptic therapy. J Clin Psychiatry. 50:1989;322-328.
27. Kane J.M. Treatment-resistant schizophrenic patients. J Clin Psychiatry. 57:(suppl 9):1996;35-40.
28. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual. 1987;Social and Behavioral Sciences Documents, San Rafael, CA.
29. Kossen M., Selten J.P., Kahn R.S. Elevated clozapine plasma level with lamotrigine. Am J Psychiatry. 158:2001;1930.
30. Leach M.J., Baxter M.G., Critchley M.A. Neurochemical and behavioural aspects of lamotrigine. Epilepsia. 32:(suppl 2):1991;S4-S8.
31. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 334:1987;1-100.
32. Marder S., David J., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis Combined results of the North American Trials . J Clin Psychiatry. 58:1997;538-546.
33. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex . J Neurosci. 42:1997;664-668.
34. Moghaddam B., Adams B.W. Reversal of phenocyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
35. Olney J.W., Newcomer J.W., Farber N.B. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry. 59:2002;467-468.
36. Overall J.E., Gorham D.E. The Brief Psychiatric Rating Scale. Psychol Rep. 10:1961;799-812.
37. Potkin S.G., Jin Y., Bunney B.G., Costa J., Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry. 156:1999;145-147.
38. Tollefson G.D., Beasley C.M. Jr, Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders Results of an international collaborative trial . Am J Psychiatry. 154:1997;457-465.
39. Tollefson G.D., Birkett M.A., Kiesler G.M., Wood A.J. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 49:2001;52-63.
40. Tollefson G.D., Sanger T.M., Lu I., Thieme M.E. Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 55:1998;250-258.
41. Tsai G.E., Yang P., Chung L.-C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 44:1998;1081-1089.
42. Tsai G.E., Yang P., Chung L.-C., Tsai I.-C., Tsai C.-W., Coyle J.T. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 156:1999;1822-1825.
43. van Berckel B.N., Hijman R., van der Linden J.A., Westenberg H.G., van Ree J.M., Kahn R.S. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 40:1996;1298-1300.